C. Tierney

J. Shepherd, Linda J Harrison, G. Siberry, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.

P. Sax, D. Haas, E. Daar, 2013, The Journal of infectious diseases.

A Randomized Clinical Trial Evaluating Therapeutic Drug Monitoring (TDM) for Protease Inhibitor–Based Regimens in Antiretroviral-Experienced HIV-Infected Individuals: Week 48 Results of the A5146 Study

C. Dykes, L. Demeter, K. Klingman, 2011, HIV clinical trials.

Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial

L. Mofenson, J. Shepherd, M. Fowler, 2021, PloS one.

Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment

E. Daar, M. Glesby, J. Andersen, 2013, AIDS.

Changes in Proteinuria and Albuminuria With Initiation of Antiretroviral Therapy: Data From a Randomized Trial Comparing Tenofovir Disoproxil Fumarate/Emtricitabine Versus Abacavir/Lamivudine

P. Sax, E. Daar, D. Kitch, 2014, Journal of acquired immune deficiency syndromes.

Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults

D. Kitch, T. Brown, G. McComsey, 2015, HIV clinical trials.

Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B

Noele P. Nelson, R. Chung, T. Puthanakit, 2018, The New England journal of medicine.

Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen

R. Chung, T. Puthanakit, S. Pol, 2016, BMC Infectious Diseases.

Hepatotoxicity and Liver-Related Mortality in Women of Child-Bearing Potential Living With HIV and High CD4 Counts Initiating Efavirenz-Containing Regimens.

J. Currier, M. Fowler, T. Chipato, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).

M. Hirsch, A. Caliendo, B. Polsky, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study

Catia Marzolini, Edward P Acosta, D. Clifford, 2004, AIDS.

Brief Report: Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women With HIV/ HBV Coinfection

D. Moodley, J. Currier, M. Fowler, 2022, Journal of acquired immune deficiency syndromes.

A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.

M A Fischl, J. Phair, M. Hirsch, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.

A. Collier, J. Rigdon, F. Aweeka, 2015, Journal of acquired immune deficiency syndromes.

Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide

P. Sax, E. Daar, K. Robertson, 2014, Annals of Internal Medicine.

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

D. Katzenstein, P. Sax, E. Daar, 2011, Annals of Internal Medicine.

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants

G. Wilding, P. Sax, E. Daar, 2017, Therapeutic drug monitoring.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Lynne Peeples, David Katzenstein, Victoria A Johnson, 2009, The New England journal of medicine.

Discordant Associations Between SLCO1B1 521T→C and Plasma Levels of Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study A5146

D. Haas, Hongyu Jiang, C. Dykes, 2013, Therapeutic drug monitoring.

Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092

P. Musoke, F. Aweeka, J. Moye, 2021, The Pediatric infectious disease journal.

Feasibility of half‐sibling designs for detecting a genetic component to a disease

N. Risch, K. Merikangas, C. Tierney, 1994, Genetic epidemiology.

Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.

S. Hammer, D. Katzenstein, R. D’Aquila, 2003, The Journal of infectious diseases.

Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis

S. Hammer, D. Katzenstein, R. Schooley, 2000 .

Infants Receiving Very Early ART Have High CD4 Counts in the First Year of Life.

S. Spector, M. Cotton, D. Persaud, 2022, Clinical Infectious Diseases.

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.

K. Tashima, D. Kuritzkes, D. Clifford, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: pharmacokinetics and safety data from a Phase I/II Proof of Concept Study

S. Spector, M. Cotton, D. Persaud, 2021 .

Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.

S. Spector, D. Persaud, E. Capparelli, 2020, The lancet. HIV.

Postpartum Viral Load Rebound in HIV-1–Infected Women Treated with Highly Active Antiretroviral Therapy: AIDS Clinical Trials Group Protocol A5150

S. Kalams, F. Aweeka, S. Cohn, 2011, HIV clinical trials.

PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150.

F. Aweeka, S. Cohn, Xin Sun, 2015, Jacobs journal of AIDS/HIV.

Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial

M. Fowler, L. Stranix-Chibanda, G. Siberry, 2021, PloS one.

Enrollment and transition challenges in the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) network’s PROMISE trial for resource-limited regions

M. Fowler, J. McIntyre, S. Brummel, 2020, Clinical trials.

HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.

D. Katzenstein, P. Sax, R. Bosch, 2012, The Journal of infectious diseases.

Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.

M. Hirsch, R. Bosch, B. Polsky, 2006, The Journal of infectious diseases.

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants

M. Hudgens, R. Haubrich, P. Sax, 2017, The Journal of infectious diseases.

Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.

S. Hammer, D. Katzenstein, H. Alexander, 2001, The Journal of infectious diseases.

Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

P. Sax, E. Daar, D. Kitch, 2014, Journal of acquired immune deficiency syndromes.

Markers of renal disease and function are associated with systemic inflammation in HIV infection

D. Kitch, G. McComsey, K. Melbourne, 2015, HIV Medicine.

Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s

P. Sax, E. Daar, D. Kitch, 2015, Journal of acquired immune deficiency syndromes.

Cystatin C-Based Renal Function Changes After Antiretroviral Initiation: A Substudy of a Randomized Trial

P. Sax, E. Daar, D. Kitch, 2014, Open forum infectious diseases.

Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe

L. Aurpibul, J. Currier, M. Fowler, 2019, AIDS and Behavior.

Randomized Study of Dual Versus Single Ritonavir-Enhanced Protease Inhibitors for Protease Inhibitor-Experienced Patients with HIV

J. Mellors, A. Collier, K. Klingman, 2008, HIV clinical trials.

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

D. Katzenstein, P. Sax, E. Daar, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial

G. Montepiedra, L. Mokgatlhe, W. El-Sadr, 2023, BMC Pregnancy and Childbirth.

Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects

J. Park, C. Flexner, C. Hendrix, 2007, Antimicrobial Agents and Chemotherapy.

Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial

D. Kuritzkes, R. Bosch, H. Ribaudo, 2000, AIDS.

Bone and Renal Health in Infants With or Without Breastmilk Exposure to Tenofovir-Based Maternal Antiretroviral Treatment in the PROMISE Randomized Trial

D. Moodley, G. Theron, M. Fowler, 2023, Journal of acquired immune deficiency syndromes.

Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.

C. Flexner, R. Gross, T. Flanigan, 2009, Archives of internal medicine.

Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.

C. Flexner, R. Gross, J. Aberg, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study

R. Parker, K. Freedberg, D. Rabideau, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202

P. Sax, E. Daar, A. Collier, 2019, Antimicrobial Agents and Chemotherapy.

Transportability from Randomized Trials to Clinical Care: On Initial HIV Treatment with Efavirenz and Suicidal Thoughts or Behaviors.

Jessie K. Edwards, S. Cole, D. Westreich, 2021, American journal of epidemiology.

A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298).

D. Richman, D. Havlir, P. Tebas, 2002, AIDS research and human retroviruses.

Comparison of Antiretroviral Therapies in Pregnant Women Living With Human Immunodeficiency Virus and Hepatitis B Virus

D. Moodley, J. Currier, M. Fowler, 2023, Obstetrics and gynecology.

Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS).

D. Ahern, A. Hallstrom, E. Schron, 1990, The American journal of cardiology.

Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment

E. Daar, M. Glesby, J. Andersen, 2013, AIDS.

Markers of renal disease and function are associated with systemic inflammation in HIV infection

D. Kitch, G. McComsey, K. Melbourne, 2015, HIV medicine.

HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study.

A. Kekitiinwa, M. Mirochnick, A. Coletti, 2023, The lancet. HIV.

Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202

D. Katzenstein, P. Sax, A. Zolopa, 2013, HIV clinical trials.

Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.

C. Flexner, R. Gross, T. Flanigan, 2009, Archives of internal medicine.

Impact of randomized antiretroviral therapy initiation on glucose metabolism

P. Sax, E. Daar, D. Kitch, 2014, AIDS.

Impact of Human Immunodeficiency Virus Drug Resistance Mutations Detected in Women Prior to Antiretroviral Therapy With Efavirenz + Tenofovir Disoproxil Fumarate + Lamivudine (or Emtricitabine)

C. Tierney, Ross S. Milne, Sheila M Styrchak, 2024, Open forum infectious diseases.